NEWS
13 Aug 2008
Encorium Group Signs $3.5 Million of New Contracts
for Vaccines Clinical Trials
$13.5 Million of New Business Contracts Announced During the
Past Three Weeks
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium Group, Inc. (Nasdaq:
ENCO), a full-service multinational contract research organization
(CRO) that provides design, development, and management capabilities
for clinical trials and patient registries to many of the
world's leading pharmaceutical and biotechnology companies,
today announced the signing of $3.5 million of new business
contracts with a global biopharmaceutical company. These contracts,
which cover clinical trials in the field of vaccines and infectious
diseases, will be conducted in multiple European countries.
Services include regulatory submissions, project management,
and field monitoring. Revenue recognition will begin in the
current quarter with the remainder expected to occur on a
proportional performance basis as services are performed on
each project.
Kenneth M. Borow, M.D., Encorium Group’s President and
Chief Medical and Strategic Development Officer, stated, “With
the signing of these contracts, Encorium has announced approximately
$13.5 million of new business during the past three weeks.
In aggregate, these new contracts represent both repeat and
new client business and cover a wide array of therapeutic
areas for multiple small as well as large biopharmaceutical
companies. Encorium will provide clinical trial services for
these studies on three continents including North America,
Europe, and South America. We are very encouraged about our
company’s ability to win new business, especially as
we move forward with our globalization efforts.”
Kai Lindevall, M.D., Ph.D., Encorium’s Chief Executive
Officer, commented, “We see these new contracts as additional
confirmation of the strength of our broad-based vaccines franchise.
We are one of the world’s most experienced contract
research organizations (CRO) involved in the development of
prophylactic vaccines. This has allowed us to recently expand
our clinical trial service offerings to include immunotherapy
(i.e., therapeutic vaccines), a growing and innovative approach
to the treatment of human disease.”
>
printer version 
22 Jul 2008
Encorium Group Signs Additional New Contracts Valued
at $5.0 Million
Approximately $10 Million of New Business Contracts Announced
During the Past Week
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium Group, Inc. (Nasdaq:
ENCO), a full-service multinational contract research organization
(CRO) that provides design, development, and management capabilities
for clinical trials and patient registries to many of the
world's leading pharmaceutical and biotechnology companies,
today announced $5.0 million of new business contracts with
several multinational as well as smaller biopharmaceutical
companies. The therapeutic areas included in these awards
are cardiovascular diseases, oncology, diabetes, and infectious
diseases. Services, which will be provided in both North America
and Europe, include medical/scientific consulting, data management,
regulatory affairs, project management, field monitoring,
and medical monitoring/writing. Revenue recognition for many
of these contracts will begin in the current third quarter
of 2008 with the remainder expected to occur on a proportional
performance basis as services are performed on each project.
Kenneth M. Borow, M.D., Encorium Group’s President and
Chief Medical and Strategic Development Officer, stated, “Encorium
has announced approximately $10 million of new business contracts
during the past week which has resulted in an increase in
our current backlog of signed contracts to approximately $43
million. We are very encouraged by these recent developments
and remain confident in our ability to continue to win new
business across a wide array of therapeutic areas and geographies.”
Kai Lindevall, M.D., Ph.D., Encorium’s Chief Executive
Officer, commented, “We feel that the successful signing
of new business and receipt of new requests for proposals
are a clear justification of our recently announced expansion
plans. Pharmaceutical and biotechnology companies are recognizing
the value of our potential therapeutic and geographic capabilities.
That is why I am delighted that we are proceeding with our
plans to acquire the oncology-focused CRO Prologue and merge
with Linkcon. We feel that with the addition of Prologue’s
therapeutic expertise and Linkcon’s expanding group
of CROs in India, Latin America and China/Asia, Encorium will
be well positioned to win large multinational CRO contracts
that have previously been difficult to attain.”
>
printer version
17 Jul 2008
Encorium Group Announces $5.1 Million New Business
Contract For A Multinational Cardiovascular Trial Of An Innovative
Anti-thrombotic Agent
WAYNE, Pa. Encorium Group, Inc. (Nasdaq: ENCO) today announced
the signing of a contract for $5.1 million with an innovative
biotechnology company for a Phase 2 clinical trial to be conducted
by Encorium in conjunction with our South American partner
Estudios Clínicos Latino América (ECLA). The
contract amount includes $170,000 payable under a letter of
intent that was announced previously. The current trial will
assess the efficacy and safety of multiple doses of a new
anti-thrombotic agent in an at-risk patient population with
cardiovascular disease. Encorium will provide full service
support, including consulting on trial design and protocol
development, project and study site management and monitoring,
data management, biostatistical analysis, safety monitoring,
and medical writing. Revenues will be recognized as services
are performed on a proportional performance basis over the
life of the contract, beginning in the current third quarter.
>
printer version
12 Jun 2008
Encorium Group, Inc. Announces Signing of Letter
of Intent to Combine with Linkcon; Expected Expansion Will
Create Global CRO
Company to Conduct Conference Call at 9:00 AM on Thursday,
June 12, 2008 to discuss
Direct link:
WEBCAST
Highlights of the Proposed Combination
• Linkcon is in the process of acquiring a series of
clinical research organizations (“CROs”) throughout
the world
• Assuming completion of its acquisitions, Linkcon is
expected to add an aggregate of $11 million in net revenue
to Encorium on a pro forma basis
• Encorium separately announced its intent to acquire
Prologue Research International, Inc. (“Prologue”),
a clinical research organization that specializes in a full
range of clinical research services for Phase I through IV
clinical trials in oncology and oncology-related studies
• Total combined company is expected to offer greatly
enhanced global capabilities and therapeutic expertise in
the North America, Europe and emerging markets including India,
Latin American and China.
• Combined backlog (including Encorium, Linkcon and
Prologue) in the range of $65-70 million expected at closing
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium Group, Inc. (Nasdaq:
ENCO) (“Encorium” or “the Company”),
a full-service multinational CRO that provides design, development,
and management capabilities for clinical trials and patient
registries to many of the world's leading pharmaceutical and
biotechnology companies, today announced that it has entered
into a non-binding letter of intent to combine (“the
Business Combination”) with Fine Success Investments,
Ltd., a British Virgin Islands company doing business as Linkcon
(“Linkcon”). Linkcon has acquired or will acquire
either prior to or simultaneously with the proposed business
combination with Encorium:
1) a CRO based in India with over 10 years of clinical trial
experience;
2) a CRO operating throughout Latin America, also with over
10 years of clinical trial experience;
3) a Chinese CRO that holds licenses to conduct clinical trials
in the People's Republic of China and Hong Kong; and
4) a controlling interest in the Chinese company that holds
the license for JK1, a healthcare portal for medical professionals
and consumers promoting the exchange of medical information
between China and the Western world.
This Business Combination is expected to enhance Encorium’s
global profile as a CRO by broadening the Company’s
operational services and therapeutic area offerings into established
and emerging biopharmaceutical markets across multiple continents.
>
printer version
12 Jun 2008
Encorium Group, Inc. Announces Signing of Letter
of Intent to Acquire Prologue Research International, Inc.
Highlights
• Prologue is a specialty clinical research organization
(“CRO”) focusing on oncology and oncology-related
studies. This acquisition broadens Encorium’s therapeutic
area expertise in this very important and high-growth area
of drug/biologics development.
• Prologue’s annual revenue grew at a compounded
rate of greater than 30% from 2005 through 2007.
• Prologue has a backlog in excess of $25 million for
the fiscal year ended December 31, 2007.
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium Group, Inc. (Nasdaq:
ENCO) (“Encorium” or “the Company”),
a full-service, multinational CRO that provides design, development,
and management capabilities for clinical trials and patient
registries to many of the world's leading pharmaceutical and
biotechnology companies, today announced that it has entered
into a non-binding letter of intent to acquire Prologue Research
International, Inc. (“Prologue”), a CRO that specializes
in a full range of clinical research services for Phase I
through Phase IV clinical trials in oncology and oncology-related
studies.
>
printer version
11 Jun 2008
Encorium
Group, Inc. Conference Call To Discuss Recent Announcements
Thursday, June 12, 2008 - 9:00 AM ET
Direct link:
WEBCAST
31 Mar 2008
Encorium Group, Inc. Announces $3.2 Million of New
Business Contracts for Europe and North America
WAYNE, Pa.--(BUSINESS WIRE)-- Encorium Group, Inc.
(Nasdaq: ENCO), a full-service multinational contract research
organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical and biotechnology
companies, today announced $3.2 million of additional new
business contracts for Europe and North America. The therapeutic
areas included in these awards are oncology, asthma, diabetes,
rheumatology, and immunology/vaccines. Services to be provided
include consulting, regulatory affairs, project management,
field monitoring, and medical monitoring/writing. Revenue
recognition for many of these contracts will begin in the
current second quarter of 2008 with the remainder expected
to occur on a proportional performance basis as services are
performed on each project.
>
printer version
15 May 2008
Encorium Group, Inc. 2008 1st Quarter Financial Results
Webcast
Thursday, May 15, 2008 at 11:00 AM ET
Direct link:
WEBCAST
28 Apr 2008
Encorium Group, Inc. expands its European operations
with the opening of an office in the Cologne area, Germany,
Encorium Germany GmbH
WAYNE, PA, April 28, 2008 – Encorium Group,
Inc. (Nasdaq: ENCO) a global clinical research organization
(CRO) specializing in the design and management of complex
clinical trials and Patient Registries for the pharmaceutical,
biotechnology and medical device industries, announces the
opening of an office in Erftstadt, Germany.
Encorium has successfully been operating in Germany through
the last years with regionally located staff and in order
to continue providing our clients with quality in clinical
research we have now established an office in Erftstadt, Germany.
Christine Mohlberg, MSc., has been appointed as Country Manager
for the operations in Germany. Christine brings more than
10 years experience in clinical research from both the pharmaceutical
and CRO industry. Christine has extensive experience as a
project leader working on a global scale and brings a wealth
of experience in CNS and oncology.
>
printer version
7 Apr 2008
Encorium Group, Inc. Announces Additional $2.2 Million
of New Business Contracts With Multiple European and U.S.
Biopharmaceutical Companies
WAYNE, PA, April 7, 2008 -- (BUSINESS WIRE)-- Encorium
Group, Inc. (Nasdaq: ENCO), a full-service multinational contract
research organization (CRO) that provides design, development,
and management capabilities for clinical trials and patient
registries to many of the world's leading pharmaceutical and
biotechnology companies, today announced that it has signed
additional new business contracts valued at approximately
$2.2 million with multiple European and U.S. biopharmaceutical
companies. The therapeutic areas included in these awards
are oncology, pulmonary arterial hypertension, infectious
diseases, immunology/vaccines, and women’s health. Services
to be provided include consulting, regulatory affairs, project
management, field monitoring, and medical monitoring/writing.
Revenue recognition is expected to occur on a proportional
performance basis as services are performed on each project.
>
printer version
31 Mar 2008
Encorium Group, Inc. Announces $1.6 Million Contract
for a Phase 2 Trial of an Innovative Immunotherapeutic Vaccine
for the Treatment of Hypertension
WAYNE, PA, March 31, 2008 -- Encorium Group, Inc.
(Nasdaq: ENCO), a full-service multinational contract research
organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries
for many of the world's leading pharmaceutical and biotechnology
companies today announced the signing of a $1.6 million contract
with Protherics, a leading UK biopharmaceutical company, for
a Phase 2 trial of its novel immunotherapeutic vaccine, Angiotensin
Therapeutic Vaccine (ATV), for the treatment of hypertension.
>
printer version
26 Mar 2008
Encorium Group, Inc. 2007 4th Quarter Financial Results
Webcast
Wednesday, March 26, 2008 at 11:00 AM ET
Direct link:
WEBCAST
21 Feb 2008
Encorium Group, Inc. Announces Realignment Of Its
Senior Management Team To Meet Its Global Growth Objectives
WAYNE, PA, February 21, 2008 – Encorium Group,
Inc. (Nasdaq: ENCO), in order to more effectively support
its global growth plans, announced that it is realigning the
responsibilities of its senior management team. These changes
are intended to facilitate globalization of Encorium through
expansion of the Company’s worldwide service offerings
with a focus on sustained revenue growth and profitability.
Dr. Kenneth M. Borow is currently President of Encorium Group,
Inc as well as Chief Executive Officer. In order to allow
Dr. Borow to focus more of his time on the expansion of the
Company’s Consultancy Services business and its Global
Business Development initiatives, the responsibilities of
Chief Executive Officer have been transferred as of today
to Dr. Kai Lindevall, presently Encorium’s President
of Operations for Europe and Asia. Dr. Borow will remain President
of the Company as well as assume the new position of Chief
Medical and Strategic Development Officer.
>
printer version
18 Jan 2008
Encorium Group, Inc. Announces $3.4 Million of Awarded
New Business Contracts
WAYNE, PA, January 18, 2008 -- Encorium Group, Inc.
(Nasdaq: ENCO), a full-service multinational contract research
organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical and biotechnology
companies, today announced it has been awarded new business
contracts with an aggregate value of approximately $3.4 million.
The therapeutic areas included in these awards are oncology,
gynecology, respiratory diseases, and gastroenterology. Services
to be provided include project management, field monitoring,
data management, statistics, medical writing, and quality
assurance. Revenue recognition for several of these contracts
began in the fourth quarter of 2007, with the remainder beginning
in the current first quarter of 2008. Revenue recognition
will occur on a proportional performance basis as services
are performed on each project.
Kenneth M. Borow, M.D., President and Chief Executive Officer
for Encorium Group, commented, “In the past two weeks
Encorium has announced $7.1 million of new business awards.
These have been over a wide array of therapeutic areas and
have included many different services that will be provided
to our clients. The work associated with these opportunities
will be performed on a multinational basis.”
>
printer version
10 Jan 2008
Encorium Group, Inc. Announces Signing of $1.7 Million
in Contracts with Leading International Biotechnology Company
for Clinical Trials in Oncology and Rheumatology
WAYNE, PA, January 10, 2008 -- Encorium Group, Inc.
(Nasdaq: ENCO), a full-service multinational contract research
organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical and biotechnology
companies today announced the signing of multiple new contracts
with an aggregate value of approximately $1.7 million. These
contracts, which are with a leading international biotechnology
company, are for regulatory submission services, support of
new clinical trials, and changes-of-scope for existing studies.
The therapeutic areas covered in these contracts are oncology
and rheumatology. Revenue recognition began during the fourth
quarter of 2007 and continues on a proportional performance
basis over the life of the contract as services are performed.
>
printer version
7 Jan 2008
Encorium Group, Inc. Announces the Signing of a $2.0
Million Contract for Data Management Services for a Global
Pharmaceutical Company
WAYNE, PA, January 7, 2008 -- Encorium Group, Inc.
(Nasdaq: ENCO), a full-service multinational contract research
organization (CRO) that provides design, development, and
management capabilities for clinical trials and patient registries
to many of the world's leading pharmaceutical and biotechnology
companies, today announced the signing of an extension to
an existing contract for Global Data Management services valued
at approximately $2.0 million. A significant portion of the
revenue from this contract extension, which was signed during
the fourth quarter, is expected to be recognized during the
first half of 2008 as services are performed.
>
printer version
|
